448 related articles for article (PubMed ID: 12727809)
1. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
[TBL] [Abstract][Full Text] [Related]
2. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice.
Grippo PJ; Nowlin PS; Demeure MJ; Longnecker DS; Sandgren EP
Cancer Res; 2003 May; 63(9):2016-9. PubMed ID: 12727811
[TBL] [Abstract][Full Text] [Related]
3. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
[TBL] [Abstract][Full Text] [Related]
4. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
5. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C; Hahn SA; Hruban RH; Redston MS; Yeo CJ; Kern SE
Cancer Res; 1994 Jul; 54(13):3568-73. PubMed ID: 8012983
[TBL] [Abstract][Full Text] [Related]
6. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.
Cerny WL; Mangold KA; Scarpelli DG
Cancer Res; 1992 Aug; 52(16):4507-13. PubMed ID: 1643642
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells.
Agbunag C; Bar-Sagi D
Cancer Res; 2004 Aug; 64(16):5659-63. PubMed ID: 15313904
[TBL] [Abstract][Full Text] [Related]
8. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN.
Siveke JT; Einwächter H; Sipos B; Lubeseder-Martellato C; Klöppel G; Schmid RM
Cancer Cell; 2007 Sep; 12(3):266-79. PubMed ID: 17785207
[TBL] [Abstract][Full Text] [Related]
9. DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union.
Shimotake T; Aoi S; Tomiyama H; Iwai N
J Pediatr Surg; 2003 May; 38(5):694-7. PubMed ID: 12720172
[TBL] [Abstract][Full Text] [Related]
10. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
[TBL] [Abstract][Full Text] [Related]
11. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
[TBL] [Abstract][Full Text] [Related]
12. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
13. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.
Laghi L; Orbetegli O; Bianchi P; Zerbi A; Di Carlo V; Boland CR; Malesci A
Oncogene; 2002 Jun; 21(27):4301-6. PubMed ID: 12082617
[TBL] [Abstract][Full Text] [Related]
14. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
Ueda S; Fukamachi K; Matsuoka Y; Takasuka N; Takeshita F; Naito A; Iigo M; Alexander DB; Moore MA; Saito I; Ochiya T; Tsuda H
Carcinogenesis; 2006 Dec; 27(12):2497-510. PubMed ID: 16774944
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
16. [Differential genetic pathway of duct and acinar carcinomas of the pancreas].
Tsutsumi M
Gan To Kagaku Ryoho; 2005 May; 32(5):593-8. PubMed ID: 15918556
[TBL] [Abstract][Full Text] [Related]
17. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
18. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
19. K-ras mutation in focal proliferative lesions of human pancreas.
Terhune PG; Phifer DM; Tosteson TD; Longnecker DS
Cancer Epidemiol Biomarkers Prev; 1998 Jun; 7(6):515-21. PubMed ID: 9641496
[TBL] [Abstract][Full Text] [Related]
20. Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.
Müller-Decker K; Fürstenberger G; Annan N; Kucher D; Pohl-Arnold A; Steinbauer B; Esposito I; Chiblak S; Friess H; Schirmacher P; Berger I
Gastroenterology; 2006 Jun; 130(7):2165-78. PubMed ID: 16762637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
